Latest News and Press Releases

STOCKHOLM, Sweden, May 10, 2004 (PRIMEZONE) -- Biovitrum AB and The Danish biotech company Symphogen A/S have signed a fee-for-service agreement, which involves process development and production of...

STOCKHOLM, Sweden, April 28, 2004 (PRIMEZONE) -- Biovitrum AB has agreed with Synaptic Pharmaceutical Corporation to license a novel and competitive project within the field of metabolic diseases....

STOCKHOLM, Sweden, Jan. 26, 2004 (PRIMEZONE) -- Biovitrum has signed an agreement with Wyeth (NYSE: WYE) to be the sole supplier of its recombinant factor VIII drug ReFacto(R), for the treatment of...

STOCKHOLM, Sweden and ST. LOUIS, Dec. 08, 2003 (PRIMEZONE) -- Tripos, Inc. (Nasdaq:TRPS) and the Swedish biotech company Biovitrum today announced positive results from the companies' discovery...

STOCKHOLM, Sweden, Oct. 28, 2003 (PRIMEZONE) -- Biotechnology company Biovitrum, has established a new business unit, Biovitrum Biopharmaceuticals, with the purpose of strengthening its position as a...

STOCKHOLM, Sweden, Sept. 08, 2003 (PRIMEZONE) -- Amgen Inc. (Nasdaq:AMGN) and Biovitrum AB today announced that they have signed a multifaceted agreement under which Amgen receives exclusive rights...

STOCKHOLM, Sweden, May 22, 2003 (PRIMEZONE) -- Biovitrum AB today announced that Biovitrum and GlaxoSmithKline (Other OTC:GLAXF) have jointly decided to focus their efforts on the development of...

STOCKHOLM, Sweden, April 7, 2003 (PRIMEZONE) -- Biovitrum today announced the start of a clinical Phase IIb study of the anti-obesity compound BVT.933 (GW876167), a 5-HT2C receptor agonist for the...

STOCKHOLM, Sweden, March 25, 2003 (PRIMEZONE) -- Biovitrum today announced the initiation of a Phase II clinical trial of BVT.3498, its lead compound for type 2 diabetes. The primary end-point of the...

STOCKHOLM, Sweden, Jan. 14, 2003 (PRIMEZONE) -- Biovitrum AB today announces a commission agreement with the Danish pharmaceutical company Lundbeck A/S for the production of a protein...